Business Description
Renascience Inc
ISIN : JP3981100005
Share Class Description:
TSE:4889: Ordinary SharesDescription
Renascience Inc is engaged in the research and development of new medical solutions by utilizing various modalities such as pharmaceuticals, medical devices, artificial intelligence and others to solve problems in the medical setting.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.75 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -1.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 5.49 | |||||
Beneish M-Score | -3.42 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.4 | |||||
3-Year EBITDA Growth Rate | -21.2 | |||||
3-Year EPS without NRI Growth Rate | -20.8 | |||||
3-Year FCF Growth Rate | -15.8 | |||||
3-Year Book Growth Rate | 42.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 70.25 | |||||
9-Day RSI | 58.79 | |||||
14-Day RSI | 54.81 | |||||
6-1 Month Momentum % | -16.59 | |||||
12-1 Month Momentum % | -33.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 16.24 | |||||
Quick Ratio | 16.24 | |||||
Cash Ratio | 15.65 | |||||
Days Sales Outstanding | 20.99 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | -2.13 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -172.55 | |||||
Net Margin % | -173.36 | |||||
FCF Margin % | -149.94 | |||||
ROE % | -18.19 | |||||
ROA % | -14.7 | |||||
ROIC % | -698.63 | |||||
ROC (Joel Greenblatt) % | -2524.57 | |||||
ROCE % | -15.27 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 24.26 | |||||
PB Ratio | 2.82 | |||||
Price-to-Tangible-Book | 2.82 | |||||
EV-to-EBIT | -8.93 | |||||
EV-to-EBITDA | -8.93 | |||||
EV-to-Revenue | 15.42 | |||||
EV-to-FCF | -9.35 | |||||
Price-to-Net-Current-Asset-Value | 2.83 | |||||
Price-to-Net-Cash | 2.97 | |||||
Earnings Yield (Greenblatt) % | -11.2 | |||||
FCF Yield % | -6.18 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Renascience Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil 円) | 191.316 | ||
EPS (TTM) (円) | -26.093 | ||
Beta | 0 | ||
Volatility % | 19.17 | ||
14-Day RSI | 54.81 | ||
14-Day ATR (円) | 17.53036 | ||
20-Day SMA (円) | 359.95 | ||
12-1 Month Momentum % | -33.33 | ||
52-Week Range (円) | 328 - 584 | ||
Shares Outstanding (Mil) | 12.71 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Renascience Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Renascience Inc Stock Events
Event | Date | Price(円) | ||
---|---|---|---|---|
No Event Data |
Renascience Inc Frequently Asked Questions
What is Renascience Inc(TSE:4889)'s stock price today?
The current price of TSE:4889 is 円365.00. The 52 week high of TSE:4889 is 円584.00 and 52 week low is 円328.00.
When is next earnings date of Renascience Inc(TSE:4889)?
The next earnings date of Renascience Inc(TSE:4889) is .
Does Renascience Inc(TSE:4889) pay dividends? If so, how much?
Renascience Inc(TSE:4889) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |